Highlights from the SWG
Events
Participation in the 19th European LeukemiaNet (ELN) Symposium
Location and date
This event was held in Mannheim, Germany, on April 18, 2023.
Chairs
- D. Hoelzer
- S. Chiaretti
Topics
- Blinatumomab Frontline HOVON Trial. (A. Rijneveld, Netherlands)
- Inotuzumab ozogamicin in MRD+ ALL. (G. Marconi, Italy)
- Blina-Venetoclax in R/R or MRD+ ALL. (C. Baldus, Germany)
- Real-life use of Venetoclax-Navitoclax, (F. Malfona, Italy)
- Update of the D-ALBA Trial. (S. Chiaretti, Italy)
- Allo-SCT in CR1, part. in Ph+/Ph-like ALL. (J. Ribera, Spain)
- Progress on T-ALL: GMALL Experience. (N. Gökbuget, Germany)
EWALL Meeting
Location and date
This event was held in Krakow, Poland, on June 23–24, 2023.
Chairs
- Sebastian Giebel
- Anna Czyżs
Program—Friday, June 23, 2023
15:00–15:10
Welcome Day 1 (Sebastian Giebel, Poland).
15:10–15:30
EWALL Organization Issues (chair: Adele Fielding).
15:30–17:00
National adult ALL studies (chair: Sebastian Giebel, Poland):
- Upfront Blinatumomab in First Line Therapy of ALL – First Results of Phase 2 HOVON 146 Study (Anita Rijneveld, Holland)
- Frontline Consolidation with Blinatumomab for High-Risk Ph(-) ALL. Update of the Graall-2014-QUEST study (Nicolas Boissel, France)
- UKALL60+ trial in older persons (Adele Fielding, UK)
- Obinutuzumab versus Rituximab for adults with ALL (OVERALL PALG ALL7 trial) (Sebastian Giebel, Poland)
- Impact of dose modifications of PEG Asparaginase on the results of the ALL2019 trial. Interim analysis (Anna Torrent, Spain)
- Analysis of MRD-oriented alloHSCT vs. early alloHSCT for adult KMT2A ALL (Jordi Ribera, Spain)
- Comparison of results of ALLHR 03+ALLHR11 trials vs. those of ALL2019 trial on T-ALL according to RAS mutations (Eulalia Genescà, Spain)
17:15–18:15
Ongoing and Future Collaborative Projects (chair: Philippe Rousselot):
- New EWALL INO2 proposal (Philippe Rousselot, France)
- Status of the HARMONY & HARMONY+ Projects (Jordi Ribera, Spain)
- Brexucabtagene autoleucel for the treatment of adults with R/R ALL. Experience from clinical practice (panel discussion)
Program—Saturday, June 24, 2023
08:50–09:00
Welcome Day 2 (Anna Czyż, Poland).
09:00–10:15
R/R ALL - approaches to personalized treatment (chair: Adele Fielding):
- Personalized treatment of R/R B-ALL using gilteritinib, everolimus or trametinib + dexamethasone. PALG GET-DEX study. (Ewa Lech-Marańda, Poland)
- R/R T-ALL based on oncogenetic, drug testing, and targeted therapy: ALL-TARGET (Philippe Rousselot, France)
- Ser/Thr and Tyr kinase activity profiling and panel RNA sequencing to drive treatment decisions in ALL. (Eliza Głodkowska-Mrówka, Poland)
10:30–11:30
Miscellaneous (chair: Anna Czyż, Poland):
- GRAALL-2014 trial aiming at reducing TRM and alloHSCT based on early MRD (Nicolas Boissel, France)
- Recent EBMT studies on alloHCT in ALL (Sebastian Giebel, Poland)
Advancements
- Incorporation of immunotherapy in frontline therapy of adult ALL in national and in an EWALL-initiated phase 3 trial (ACCADEMIA, in preparation).
- Multicenter EWALL phase 3 trials for adults with newly diagnosed B-cell precursor ALL and T-ALL (under development).
- Development of an EWALL guideline for diagnosis and management of adult ALL (manuscript accepted in Blood).
Forthcoming activities
- Development of a phase 3 trial incorporating blinatumomab in first-line therapy for young adults (18-60 yr) with Ph-negative ALL.
- Development of a pragmatic trial for R/R T-ALL.
- Development of a phase 3 trial incorporating BH3 mimetics in newly diagnosed young adults (18-60 yr) with T-ALL.
Back